pharmaceutical costs

Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watchAlthough drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
Top four approaches to reduce pharmaceutical costs
Top four approaches to reduce pharmaceutical costsMCOs are fighting back against rising pharmaceutical costs. Here are the top strategies they are embracing.
Value-based drug contracting shifts risk to manufacturersValue-based drug contracting between manufacturers and payers is picking up steam—appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.
Top 3 roadblocks to medication adherence and how to avoid themHere are the top three reasons for medication adherence failure and how to overcome them.
Payers strategize to manage opioid useHow managed care organizations manage opioid utilization and some of the limitations to those management strategies was a hot topic at the AMCP Annual Meeting.
Five things to know about Trump’s FDA lead pick GottliebOn March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.
Opinion: More industry-stakeholders play blame game for high drug costsOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
Independent Pharmacy Cooperative and Pace Alliance Join Together
Independent Pharmacy Cooperative and Pace Alliance Join TogetherIPC and Pace Alliance join together to help the independent pharmacist.
New diabetes medications help address linked diseasesExperts share updates on new diabetes medications, and provide an overview of what’s coming.
Watch list 2017: Top therapeutic areas
Watch list 2017: Top therapeutic areasFind out about the latest treatment and drug pipeline developments